ALS patients press FDA for quick access to controversial biotech drug – The Washington Post

This is a good even handed report about Genervon efforts including social media to win fast track FDA approval for GM604 for ALS. I’ve been pushing for faster review but Genervon hasn’t published any real data, just a public relations campaign which falls short of science. They’ve exasperated their clinical investigators at Columbia and Massachusetts General.

It wouldn’t take much for me to want to try it. But it will take something more than a prayer.